Retatrutide is a novel, first-in-class triple agonist peptide currently in advanced clinical research stages. It simultaneously activates receptors for GIP, GLP-1, and Glucagon—three key incretin and metabolic hormones. This multi-targeted approach has shown remarkable potential in research for supporting profound glucose control, healthy insulin sensitivity, and sustainable weight management, representing a significant leap forward in metabolic peptide science.